Patents by Inventor Anthony H. Futerman

Anthony H. Futerman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • VARIANTS OF BETA-GLUCOCEREBROSIDASE FOR USE IN TREATING GAUCHER DISEASE
    Publication number: 20230132790
    Abstract: A genetically modified human beta-glucocerebrosidase (GCase) is disclosed. The genetically modified GCase comprising an amino acid sequence at least 85% identical to SEQ ID NO: 2; and comprising mutations at coordinates L34P, K224N/G, T369E and N370D, where the coordinates correspond to said SEQ ID NO: 2; and capable of catalyzing hydrolysis of a glycolipid glucosylceramide (GlcCer). Pharmaceutical compositions comprising the genetically modified GCase and therapeutic methods of using same are also disclosed.
    Type: Application
    Filed: March 29, 2021
    Publication date: May 4, 2023
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Anthony H. FUTERMAN, Israel SILMAN, Joel L. SUSSMAN, Sarel FLEISHMAN, Adi GOLDENZWEIG, Sarka POKORNA, Yaacov ASHANI, Olga KHERSONSKY
  • Sphingosine analogs and use thereof against bacterial lung infections
    Patent number: 11471430
    Abstract: Provided herein is a group of sphingosine analogs, useful in the treatment of bacterial infections in mucosal surfaces such as lungs, caused by pathogenic bacteria which are typical to disorders and diseases such as CF and COPD.
    Type: Grant
    Filed: July 17, 2019
    Date of Patent: October 18, 2022
    Assignees: Yeda Research and Development Co. Ltd., University of Duisburg-Essen
    Inventors: Anthony H. Futerman, Tammar Joseph, Walter A. Shaw, Stephen W. Burgess, Shengrong Li
  • SPHINGOSINE ANALOGS AND USE THEREOF AGAINST BACTERIAL LUNG INFECTIONS
    Publication number: 20210275473
    Abstract: Provided herein is a group of sphingosine analogs, useful in the treatment of bacterial infections in mucosal surfaces such as lungs, caused by pathogenic bacteria which are typical to disorders and diseases such as CF and COPD.
    Type: Application
    Filed: July 17, 2019
    Publication date: September 9, 2021
    Applicants: Yeda Research and Development Co. Ltd., University of Duisburg-Essen
    Inventors: Anthony H. FUTERMAN, Tammar JOSEPH, Walter A. SHAW, Stephen W. BURGESS, Shengrong LI
  • Methods of screening for inhibitors of phospholipid synthesis related to glycolipid-storage diseases
    Patent number: 7429460
    Abstract: The present invention discloses methods of screening for identification of compounds that inhibit novel targets in the enzymatic pathway of phospholipid synthesis that are related to glycolipid storage diseases, and use of the compounds for treating patients affected with glycolipid storage diseases, particularly Gaucher disease. Specifically, the compounds of the present invention are intended to inhibit the accumulation of phosphatidylcholine (PC), wherein PC accumulation is increased due to the activation of CTP:phosphocholine cytidylyltransferase (CCT) upon glucosylceramide (GlcCer) accumulation.
    Type: Grant
    Filed: January 15, 2003
    Date of Patent: September 30, 2008
    Assignee: Yeda Research and Development Co., Ltd.
    Inventors: Anthony H. Futerman, Jacques Bodennec, Dori Pelled
  • Methods of screening for inhibitors of phospholipid synthesis related to glycolipid-storage diseases
    Publication number: 20040137531
    Abstract: The present invention discloses methods of screening for identification of compounds that inhibit novel targets in the enzymatic pathway of phospholipid synthesis that are related to glycolipid storage diseases, and use of the compounds for treating patients affected with glycolipid storage diseases, particularly Gaucher disease. Specifically, the compounds of the present invention are intended to inhibit the accumulation of phosphatidylcholine (PC), wherein PC accumulation is increased due to the activation of CTP:phosphocholine cytidylyltransferase (CCT) upon glucosylceramide (GlcCer) accumulation.
    Type: Application
    Filed: January 15, 2003
    Publication date: July 15, 2004
    Inventors: Anthony H. Futerman, Jacques Bodennec, Dori Pelled, Christian Riebeling, Selena Trajkovic